Several features of inflammation at the patients with atopic bronchial asthma when exposed to respiratory viruses

Abstract

The modern interpretation of the pathogenesis bronchial asthma (ВА) emphasizes the role of systemic inflammation at the BA, since its development under the influence of specific (allergens) and non-specific factors leads to an imbalance of pro- and anti-inflammatory cytokines in the airways. It has been established that most exacerbations of BA occur due to the influence of respiratory viral infection (RVI). The process of inflammation in the airways with virus-induced exacerbations of BA depends on the type of respiratory virus, and also phenotype and endotype of BA at the patient. Based on in vitro and in vivo studies, the role of interleukin-33 (IL-33) in the pathogenesis exacerbation of atopic BA in the mouse model is described.

The aim of our work is to determine the IL33 gene expression and study its role during development of atopic BA and its virus-induced exacerbation in humans.

Material and methods. All volunteers included in the study were divided into groups: «BA», «BA+RVI», «RVI», «healthy donors». All study participants underwent clinical, laboratory, instrumental (spirometry), allergological, immunological examination (determination the expression mRNA of the IL33 gene in peripheral venous blood and identification the mRNA of respiratory viruses (RSV, RV, coronaviruses, influenza virus type A and B, metapnevmovi-ruses, adenoviruses, bokaviruses, parainfluenza viruses type 1, 2, 3, 4) in smears from the nasal cavity by RT-PCR).

Results. In the «BA» and «BA+RVI» groups were observed the decrease FEV1, increased the ACQ-7 (more than 1.5 points), the blood eosinophilia (P = 0.000002), which characterizes the uncontrolled course and exacerbation of atopic BA from volunteers. The highest level of the expression mRNA IL-33 was found at the «BA+RVI» group (P = 0.003), and in the absence of RVI in volunteers with exacerbation of atopic BA the level of IL-33 not differs from healthy donors. According to the results of our study the more severe course of atopic BA was observed in the season with a predominance of RSV infection in 2017 compared to 2016 according to ACQ-7 (P = 0.00004 and P = 0.0002) and FEV1 (P = 0.006 and P = 0.008), respectively.

Conclusions. The results of the study provide additional evidence of the role of pro-inflammatory IL-33 in the pathogenesis of RVI and virus-induced exacerbations of atopic BA (most often RSV and RV). Identification of new mechanisms of virus-induced exacerbations of atopic BA can be used in the selection and development of personalized basic therapy of asthma.

Keywords:bronchial asthma; interleukins; cytokines; respiratory viral infection; respiratory syncytial viruses; rhino-viruses

For citation: Galitskaya M.A., Kurbacheva O.M., Shilovskiy I.R, Nikolsky A.A., Nikonova A.A., Dyneva M.E., Khaitov M.R. Several features of inflammation at the patients with atopic bronchial asthma when exposed to respiratory viruses. Immunologiya. 2019; 41 (2): 154-63. DOI: 10.33029/0206-4952-2020-41-2-154-163 (in Russian)

Funding. Work was financially supported by the Russian Science Foundation grant No. 19-15-00272.

Conflict of interests. The authors declare no conflict of interests.

References

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2016 update). GINA. 2016. URL: www.ginasthma.org. (date of access April 14, 2017)

2. Federal clinical guidelines for the diagnosis and treatment of bronchial asthma. 2016. URL: www.pulmonology.ru. (date of access September 6, 2017) (in Russian)

3. National program «Bronchial asthma in children. Treatment Strategy and Prevention». 2012 (IV edition) (in Russian)

4. Heffler E., Bagnasco D., Canonica G.W. Strategies to reduce corticosteroid-related adverse events in asthma. Curr. Opin. Allergy Clin. Immunol 2019; 19 (1): 61–7.

5. Galitskaya M.A., Kurbacheva O.M. The modern ideas about the role of innate and adaptive immunity in bronchial asthma. Rossiyskiy allergologicheskiy zhurnal. 2018; 6: 7–17 (in Russian)

6. Shilovskiy I.P., Eroshkina D.V., Babakhin A.A., Khaitov M.R. Anticytokine therapy of allergic asthma. Mol. Biol. 2017; 51 (1): 1825–48.

7. Salter B.M., Oliveria J.P., Nusca G., Smith S.G., et al. IL-25 and IL-33 induce Type 2 inflammation in basophils from subjects with allergic asthma. Respir. Res. 2016; 17: 5.

8. Prefontaine D., Nadigel J., Chouiali F., Audusseau S., et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J. Allergy Clin. Immunol. 2010; 125 (3): 752–4.

9. Liu X., Hammel M., He Y.F., Tainer J.A., et al. Structural insights into the interaction of IL-33 with its receptors. Proc. Natl Acad. Sci. USA. 2013; 110 (37): 14 918–23.

10. Bagautdinova G.E., Karimov D.O., Mukhammadieva G.F., Shagalina A.U., Bakirov A.B. Role of the polymorphic locus rS3939286 IL33 gene in the development of allergic rhinitis in workers allelopathic productions. Immunologiya. 2016; 37 (2): 76–8. (in Russian)

11. Khaitov M.R., Gaisina A.R., Shilovskiy I.P., Smirnov V.V., et al. The role of interleukin-33 in pathogenesis of bronchial asthma. New experimental data. Biochemistry (Moscow). 2018; 83 (1): 13–25.

12. Jackson D.J., Gangnon R.E., Evans M.D., Roberg K.A., et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am. J. Respir. Crit. Care Med. 2008; 178 (7): 667–72.

13. Jackson D.J., Johnston S.L. The role of viruses in acute exacerbations of asthma. J. Allergy Clin. Immunol. 2010; 125 (6): 1178–87.

14. Plaza V., Ramos-Barbón D., Muñoz A.M., Fortuna A.M., et al. Exhaled nitric oxide fraction as an add-on to ACQ-7 for not well controlled asthma detection. PLoS One. 2013; 25 (10): e77085.

15. Makrinioti H., Toussaint M., Jackson D.J., Walton R.P., et al. Role of interleukin 33 in respiratory allergy and asthma. Lancet Respir. Med 2014; 2 (3): 226–37.

16. Xia J., Zhao J.L., Shang J., Li M., et al. Increased IL-33 expression in chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015; 308 (7): L619–27.

17. Furukawa S., Moriyama M., Miyake K., Nakashima H., et al. Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease. Sci. Rep 2017; 7 (42413): 1–10.

18. Nile C.J., Barksby E., Jitprasertwong P., Preshaw P.M., et al. Expression and regulation of interleukin-33 in human monocytes. Immunology. 2010; 130 (2): 172–80.

19. Khaitov M.R., Shilovskiy I.P., Nikonova A.A., Shershakova N.N., et al. Small interfering RNAs targeted to interleukin-4 and respiratory syncytial virus reduce airway inflammation in a mouse model of virus-induced asthma exacerbation. Hum. Gene Ther. 2014; 25 (7): 642–50.

20. Pecaric-Petkovic T., Didichenko S.A., Kaempfer S., Spiegl N., et al. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009; 113 (7): 1526–34.

21. Galitskaya M.A., Shilovskiy I.P., Nikonova A.A., Gaisina A.R., et al. Increased il-33 expression in atopic bronchial asthma patients with confirmed viral respiratory infection. Allergy. 2018; 73 (105): 298.

22. Newcomb D.C., Peebles R.S. Jr. Bugs and asthma: a different disease? Proc. Am. Thorac. Soc. 2009; 6 (3): 266–71.

23. Dyneva M., Kurbacheva O., Shilovskiy I., Kovchina V., et al. Analysis of the expression of Th-1, Th-2, Th-17 cytokines in patients with allergic and non- allergic bronchial asthma associated with chronic rhinosinusitis with nasal polyps. Allergy. 2019; 74 (106): PD0361.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)


JOURNALS of «GEOTAR-Media»